Wallet provider Exodus expects a net loss of $11 million in 2025.
BlockBeats News, March 12, according to official sources, wallet provider Exodus Movement, Inc. reported a net loss of $11.4 million for the full year of 2025, while achieving a net profit of $113 million in 2024.
Although the company reported record annual revenue of $121.6 million, a 5% year-over-year increase, it still incurred a loss. The record revenue was attributed to the growth of its business-to-business product, XO Swap. The company stated that its annual swap transaction volume grew by 21% to $6.89 billion, contributing 19% of fourth-quarter revenue.
The main reason for the loss was a net loss of $18.9 million in digital assets in 2025, compared to a profit of $96.1 million in 2024. Operating expenses also rose sharply, with technology, development, and user support costs increasing by 37% to $62.9 million, while general and administrative expenses grew by 68% to $66.3 million.
The downturn in the cryptocurrency market was reflected in the fourth quarter's performance, as the company's revenue dropped 34% from $44.8 million in Q4 2024 to $29.5 million. The net loss in Q4 2025 widened to $53.2 million, including a $63.6 million loss in digital assets.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Applied Digital shares surge as Q1 revenue quadruples
October 8 - ** Data center service provider Applied Digital (APLD.O) saw its stock rise 3.57% in pre-market trading to $24.66 ** The company’s Q1 revenue (link) surged more than fourfold to $341.9 millions, far surpassing analyst estimates of $133.8 millions ** Northland Capital Securities noted that APLD’s revenue and cash flow should increase significantly in the coming years as contracted data center capacity becomes operational and starts generating income ** Net loss attributable to common shareholders widened from $18.5 millions (7 cents/share) a year ago to $221 millions (76 cents/share) ** According to data compiled by London Stock Exchange Group (LSEG), the average rating from 17 analysts covering the stock is “Buy”, with a median target price of $70.00, representing an upside of about 194% from the current price ** Year-to-date, the stock is down about 2.9%, while the Nasdaq Index .IXIC is up 18.5% over the same period. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation and provides it only as a convenience. Reuters assumes no liability for any damage or loss resulting from the use of automated translation.)
WTI crude oil rises above $91 per barrel, up 3.02% intraday
WTI crude oil rose above $91 per barrel for the first time since October 2, with a daily increase of 3.02%.
AstraZeneca (AZN.US) and Daiichi Sankyo (DSNKY.US) TROP2 ADC receives approval for new indication in China
According to information from Zhihu Finance APP, AstraZeneca (AZN.US) and Daiichi Sankyo (DSNKY.US) have announced that Datroway® (generic name: datopotamab deruxtecan for injection) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not suitable for PD-1/PD-L1 inhibitor therapies. Datopotamab deruxtecan is an antibody-drug conjugate (ADC) targeting TROP2, developed with proprietary technology by Daiichi Sankyo, and jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
Abu Dhabi National Oil Company invites bids for crude oil cargo shipments
Trader: Abu Dhabi National Oil Company issued a tender this week to sell crude oil for December loading or January delivery.
Crypto prices
More
